Instil Bio Inc. (TIL) - Net Assets
Based on the latest financial reports, Instil Bio Inc. (TIL) has net assets worth $113.87 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($203.52 Million) and total liabilities ($89.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Instil Bio Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $113.87 Million |
| % of Total Assets | 55.95% |
| Annual Growth Rate | 55.48% |
| 5-Year Change | -79.49% |
| 10-Year Change | N/A |
| Growth Volatility | 1319.01 |
Instil Bio Inc. - Net Assets Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore TIL total asset value for the complete picture of this company's asset base.
Annual Net Assets for Instil Bio Inc. (2019–2025)
The table below shows the annual net assets of Instil Bio Inc. from 2019 to 2025. For live valuation and market cap data, see how much is Instil Bio Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $113.87 Million | -32.80% |
| 2024-12-31 | $169.44 Million | -24.97% |
| 2023-12-31 | $225.83 Million | -37.89% |
| 2022-12-31 | $363.61 Million | -34.51% |
| 2021-12-31 | $555.20 Million | +89.90% |
| 2020-12-31 | $292.37 Million | +3529.18% |
| 2019-12-31 | $8.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Instil Bio Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71930300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-583.00K | -0.51% |
| Other Components | $840.94 Million | 738.53% |
| Total Equity | $113.87 Million | 100.00% |
Instil Bio Inc. Competitors by Market Cap
The table below lists competitors of Instil Bio Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
$53.61 Million |
|
Metair
JSE:MTA
|
$53.64 Million |
|
Kronos Bio Inc
NASDAQ:KRON
|
$53.65 Million |
|
Top High Image
TWO:3284
|
$53.66 Million |
|
Airmate Cayman International Co Ltd
TW:1626
|
$53.57 Million |
|
Botnia Gold AB (publ)
ST:BOTX
|
$53.57 Million |
|
Kingston Resources Ltd
AU:KSN
|
$53.56 Million |
|
Wiener Privatbank SE
VI:WPB
|
$53.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Instil Bio Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 169,436,000 to 113,866,000, a change of -55,570,000 (-32.8%).
- Net loss of 71,372,000 reduced equity.
- Other comprehensive income decreased equity by 355,000.
- Other factors increased equity by 16,157,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-71.37 Million | -62.68% |
| Other Comprehensive Income | $-355.00K | -0.31% |
| Other Changes | $16.16 Million | +14.19% |
| Total Change | $- | -32.80% |
Book Value vs Market Value Analysis
This analysis compares Instil Bio Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.29x to 0.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.26 | $7.90 | x |
| 2020-12-31 | $45.61 | $7.90 | x |
| 2021-12-31 | $104.76 | $7.90 | x |
| 2022-12-31 | $56.15 | $7.90 | x |
| 2023-12-31 | $34.72 | $7.90 | x |
| 2024-12-31 | $26.03 | $7.90 | x |
| 2025-12-31 | $17.08 | $7.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Instil Bio Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.79x
- Recent ROE (-62.68%) is below the historical average (-51.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -80.11% | 0.00% | 0.00x | 1.18x | $-7.26 Million |
| 2020 | -12.91% | -27346.38% | 0.00x | 1.09x | $-66.97 Million |
| 2021 | -28.24% | 0.00% | 0.00x | 1.10x | $-212.31 Million |
| 2022 | -61.38% | 0.00% | 0.00x | 1.33x | $-259.54 Million |
| 2023 | -69.12% | 0.00% | 0.00x | 1.44x | $-178.67 Million |
| 2024 | -43.75% | 0.00% | 0.00x | 1.56x | $-91.08 Million |
| 2025 | -62.68% | 0.00% | 0.00x | 1.79x | $-82.76 Million |
Industry Comparison
This section compares Instil Bio Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Instil Bio Inc. (TIL) | $113.87 Million | -80.11% | 0.79x | $53.58 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as … Read more